The Control of Influenza

Kilbourne, Edwin D.

doi:10.1007/978-1-4684-5239-6_11

Cited by 8 publications

(6 citation statements)

References 245 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While the peak titer after influenza virus vaccination is assumed to occur 4 to 6 weeks later, we did not collect blood specimens before or after the 4-to 6-week period to determine the peak period with certainty. Peak titers have been reported to occur as early as 2 weeks and as long as 16 weeks after vaccine administration (7). The longer intervals of 8 to 16 weeks occur when adjuvants are added to the vaccine (6).…”

mentioning

confidence: 99%

Time to peak serum antibody response to influenza vaccine

Rastogi

Groß

Bonelli

et al. 1995

Clin Diagn Lab Immunol

View full text Add to dashboard Cite

The time to the appearance of a peak serum antibody response to influenza virus vaccine is not clearly defined. We compared the most commonly used time intervals described in the literature-4 and 6 weeks after vaccination. We studied 118 elderly patients from three different geographic sites. The 1992 to 1993 trivalent inactivated influenza virus vaccine containing influenza virus A/Beijing/353/89 (H3N2), influenza virus A/Texas/36/91 (H1N1), and influenza virus B/Panama/45/90 was used. No statistically significant differences were found at the 4-and 6-week intervals after vaccination.

show abstract

mentioning

confidence: 99%

Time to peak serum antibody response to influenza vaccine

Rastogi

Groß

Bonelli

et al. 1995

Clin Diagn Lab Immunol

View full text Add to dashboard Cite

show abstract

“…Quebec has legislation requiring informed consent for immunization and a verbal or written authorization from a designated person or a relative for those who are unable to provide a valid consent (9). Authorization has to be sought each season because the composition of the influenza vaccine is modified (type of viral strains and industrial process) year after year, and the risk of adverse effects may vary between different vaccines (10). The majority of residents questioned in this study desired that third-party consent be obtained annually from a family member or legal guardian should they be unable to provide consent for influenza vaccination.…”

Section: Discussionmentioning

confidence: 99%

Influenza and Pneumococcal Vaccination in Long Term Care Facilities in Two Regions of Quebec

Wals

Carbonneau

Payette

et al. 1996

Canadian Journal of Infectious Diseases and Medical Microbiolog

View full text Add to dashboard Cite

OBJECTIVES: To evaluate the use of influenza and pneumococcal vaccines in long term care facilities.DESIGN: Cross-sectional survey in a random sample of 30 facilities in two regions of Quebec. Information was collected from the general manager or the chief of nursing, all consultant physicians and a random sample of 20 residents in each facility.RESULTS: Twenty-nine centres agreed to participate. The mean influenza vaccination rate was 70%, and was not influenced by differences in the types of facilities or the organization of the programs for immunization. The main obstacle to influenza vaccination reported by physicians was nonacceptance by a significant proportion of residents. Of the residents who did not initially request influenza vaccine, only 64% accepted vaccination when it was offered. The vast majority of residents were satisfied with the information they had received and the respect shown for their freedom of choice. Forty per cent of residents were unfit to provide a valid consent and the vaccination rate was 76% in this group. Only one-third of the physicians regularly obtained authorization from a relative or the legal guardian before prescribing vaccination for incompetent residents. None of the facilities studied had an effective program for pneumococcal vaccination, only 43% of the physicians reported any use of pneumococcal vaccine and 98% of residents had never heard of the vaccine.CONCLUSIONS: The national objective of 95% coverage with influenza vaccine will be difficult to achieve in long term care facilities, mainly because a minority of residents are not likely to be convinced of the benefit of immunization. Much remains to be done to promote and administer pneumococcal vaccine in this setting.

show abstract

“…29,30 Immunity following influenza vaccination begins within 1 -2 weeks and rarely persists beyond 1 year. 31 Protective antibody levels may only last 4 months or less in certain elderly patients. In addition, the strains of influenza may differ significantly from one season to the next, thus increasing the need for annual vaccinations.…”

Section: Licensed Vaccines Influenzamentioning

confidence: 99%

“…More than 30 subtypes of human papillomavirus (HPV) are known to be sexually transmittable. Certain subtypes are associated with malignancy (16,18,31,33,45,52,58) and other subtypes are associated with condylomata (6 and 11). The few subtypes allow for more focused strategies for immunization.…”

Section: Human Papillomavirusmentioning

confidence: 99%

A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines

Huang

Tyring

2004

Journal of Infection

View full text Add to dashboard Cite

Viral vaccines could be considered among the most important medical achievements of the 20th century. They have prevented much suffering and saved many lives. Although some curative antiviral drugs exist, we desperately depend on efforts by academic, governmental and industrial scientists in the advancement of viral vaccines in the prevention and control of infectious diseases. In the next decade, we hope to see advancement in the development of current and investigational viral vaccines against childhood and adult infections. In this article, we will review the licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines.

show abstract

The Control of Influenza

Cited by 8 publications

References 245 publications

Time to peak serum antibody response to influenza vaccine

Time to peak serum antibody response to influenza vaccine

Influenza and Pneumococcal Vaccination in Long Term Care Facilities in Two Regions of Quebec

A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines

Contact Info

Product

Resources

About